KRAS and non-small cell lung carcinoma: Recently, the KRAS G12C mutation has been identified as a targetable oncogenic mutation in NSCLC with promising investigational agents currently in clinical trials [5,6,20,21], and one agent, sotorasib, recently receiving accelerated approval by the US FDA [9].